Neurotechnology Revenues Reach $110 Billion Says New Report on the Brain Industr

[Guest guest]

Neurotechnology Revenues Reach $110 Billion Says New Report on the

Brain Industry: NeuroInsights Reveals Investment Trends, Market

Opportunities

http://home.businesswire.com/portal/site/moreoveruk/index.jsp?epi-

content=GENERIC & newsId=20060419005157 & & newsLang=en & beanID=1153550781 & v

iewID=news_view

SAN FRANCISCO--(BUSINESS WIRE)--April 19, 2006--NeuroInsights, the

neurotechnology market authority, today announced the release of the

industry's second annual comprehensive investment and business

analysis of the global neurotechnology marketplace. In the report,

NeuroInsights provides a unified, market-based framework to help

investors, companies, and governments easily quantify opportunities,

determine risks, and understand the dynamics of this rapidly changing

market.

" The Neurotechnology Industry 2006 Report: Market Analysis and

Strategic Investment Guide of the Global Neurological Disease and

Psychiatric Illness Markets, " is a 330-page report tracking

developments at over 450 public and private companies involved in

neurotech. The report includes competitive analysis and clinical

trials by market segment for more than a dozen disorders, including

Alzheimer's disease, addiction, anxiety, attention disorders,

depression, epilepsy, hearing loss, insomnia, obesity, pain,

Parkinson's, schizophrenia, stroke, and other brain-related

illnesses.

The Neurotechnology Industry 2006 Report's findings include:

-- Neurotech products generated revenues of $110 billion in 2005,

with 10% growth. The three sectors contributed as follows:

neuropharmaceuticals, with revenues of $93 billion and 7% growth;

neurodevices, with revenues of $3.4 billion and 21% growth; and

neurodiagnostics, with revenues of $13.5 billion and 11% growth.

-- Venture capital investment in neurotech companies climbed 230%

from 1999 to 2005, representing nearly $7.5 billion. Today, one-in-

four VC dollars invested in life sciences goes to neurotechnology

companies.

-- NeuroInsights' Neurotech Index, an investment benchmark that

measures the stock performance of 30 publicly traded neurotechnology

companies, which was started December 31, 2003, was up 85%, as of

March 31, 2006, compared to gains of 16% in both the S & P 500 and the

NASDAQ Composite Index.

-- Neurological disease and psychiatric illness represent the largest

and fastest growing unmet medical market: over 1.5 billion people

worldwide and 100 million individuals in North America alone.

" 2005 was another solid growth year for neurotech companies, with

heavy merger and acquisition activity, " said Zack Lynch, managing

director of NeuroInsights. " In 2005, new drugs and devices were

approved for unmet medical needs in insomnia, depression, and stroke.

Substantial venture investment, particularly in specialty

pharmaceuticals and neurodevices, continues to drive future growth. "

Developments in the neurotechnology industry will be discussed at

NeuroInsights' annual Neurotech Industry Investing and Business

Conference to be held on May 18, 2006, at the Westin San Francisco in

Millbrae, California. The market-defining conference will feature 40

neurotech executives and investors discussing the critical trends

driving the development of new drugs, devices, and diagnostics for

the brain and nervous system.